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Epidermal growth factor receptor is a potential target for cancer treatment and new small-molecule tyrosine kinase inhibitor drugs
have been designed to inhibit its activity. In this work we identify potential surrogate markers of drug activity using a proteomic
analysis. Two-dimensional electrophoresis was optimised to compare expression patterns of proteins secreted from the cancer cell
lines A431 and A549 treated with Gefitinib (Iressa) vs untreated or vehicle-only-treated samples. Upregulated or downregulated
proteins were detected using Phoretix 2D image analysis software. Several proteins were then identified using matrix-assisted laser
desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. In one case, upregulation of Protein Disulphide Isomerase in
response to Gefitinib was confirmed by Western blot analysis, and the response was shown to be concentration dependent. The
identification of surrogate markers may be of use for the evaluation of new drugs, in preclinical models, in clinical trials and in the
therapy of individual patients to give optimal biological drug doses.
British Journal of Cancer (2007) 96, 284–289. doi:10.1038/sj.bjc.6603544 www.bjcancer.com
Published online 9 January 2007
& 2007 Cancer Research UK
Keywords: surrogate marker; signal transduction; epidermal growth factor receptor; proteomics; Gefitinib
                                       
Cancer is a collection of different diseases with the common feature
of uncontrolled cell growth. Treatment is complicated since the
cancer exploits the natural intracellular signalling and metabolic
pathways of the cell (Hahn and Weinberg, 2002), often making
treatments toxic to both healthy and cancerous cells. The study of
the molecular biology of cancer has identified several proteins which
have potential as targets for new anticancer drugs (Sebolt-Leopold
and English, 2006) and, in some cases, laboratory preclinical
experiments have provided support that has encouraged the
development of drugs directed against these systems. These new
agents produce a more selective effect on these cells as they are
directed, in principle, specifically to the molecular changes which
distinguish cancer cells from normal cells thereby reducing toxicity to
normal tissues (Benson et al, 2006). A few drugs to these targets have
been evaluated by clinical trials, and a fraction of these have received
regulatory approval for use in certain groups of cancer patients
(Garber, 2006). Those that have progressed along this path have
proved to be quite efficacious and to have low toxicity. It is generally
acknowledged, however, that a more efficient process of evaluation
and selection would expedite this process making these more useful
drugs available at earlier times and potentially at lower cost.
Much discussion has taken place about the potential value of
surrogate markers for drug activity (Ross et al, 2005). Surrogate
markers are proteins or other molecules expressed in response to a
disease state or a drug, to predict a true end point, which in cancer
is patient survival. They also have potential value in preclinical
work allowing sequential measurements to be made in animal
models and in estimation of the optimal biological dose in mouse
and man. They may also be of use in similar studies in phase I
clinical trials and in the longer term to optimise drug dose for
individual patients. Despite the desire to obtain such reagents, the
literature does not contain many examples of such reports.
A particular class of targets, which have proved to be of value are
the proteins involved in signal transduction (Benson et al, 2006).
The family of signal transduction proteins that has received the
most attention to date are the Epidermal Growth Factor Receptor
(EGFR) family, most likely as several of its members are manifestly
involved in stimulating tumour growth and concepts of drug action
are clear (Yarden and Sliwkowski, 2001; Mosesson and Yarden,
2004; Warren and Landgraf, 2006). Examples of drugs to these
include antibodies to growth factors receptors such as Cetuximab
and Trastuzumab and small molecule tyrosine kinase inhibitors
such as Gefitinib (Iressa), Erlotinib (Tarceva) and Lapatinib
(Tykerb) (Normanno et al, 2004; Baselga and Arteaga, 2005).
Some research has been undertaken to develop surrogate
markers for these agents. One landmark study describes a
pharmacodynamic measurement of the phosphorylation state of
the EGFR in normal skin taken by biopsy from patients involved in
phase II trials of the drug Gefitinib, as a surrogate of the activation
state of the protein and therein the activity of the drug (Albanell
et al, 2002). Although this was one of the first studies of this
kind, it has the practical disadvantage that serial measurements are
difficult to obtain for ethical reasons. A more generally useful
measurement would be a serum test as a surrogate for drug activity
(Baselga, 2003). One example of this approach has been the
measurement of the levels of pro-angiogenic factors in the serum
from patients treated with an inhibitor of both VEGF and PDGF
receptors, sunitinib malate, where levels of VEGF-A and PIGF
increased and sVEGF-R2 levels decreased (Motzer et al, 2006).
Received 19 July 2006; revised 21 November 2006; accepted 22
November 2006; published online 9 January 2007
*Correspondence: Professor WJ Gullick; E-mail: w.j.gullick@kent.ac.uk
British Journal of Cancer (2007) 96, 284–289





















sGrowth factor receptor signalling is known to regulate the
expression of many genes, and some of these encode secreted
proteins. We hypothesise that inhibiting receptor signalling will
alter this balance and that it should be possible to detect such
changes and then develop them as an indirect quantitative assay
for drug action. In this paper, we present work using a proteomic
method to discover proteins secreted from model cancer cell
lines whose expression is modulated (up or down) by the signal
transduction inhibitor Gefitinib. These were detected using two-
dimensional gel electrophoresis and identified by mass spectro-
metry. In one case, further experiments using antibodies to detect
expression in complex protein mixtures showed that this altered
expression was drug dose dependent. Clearly these initial results
need to be extended to look for proteins with this behaviour which
are shared by most or all cancers of a particular type and which
can be monitored in a sensitive serum based assay. Such a test can
then be applied to serum obtained from patients during drug trials
to see if the assay has general utility.
MATERIALS AND METHODS
Cell culture
A431 and A549 cells were obtained from Cancer Research UK
(London, UK) and grown as adherent monolayers in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% Foetal
Calf Serum (FCS), 1% L-Glutamine and 1% penicillin–strepto-
mycin (Invitrogen, Paisley, Scotland).
Preparation of concentrated conditioned media to run on
2D gels
The following optimised method for preparation of concentrated
conditioned media was used. Thirty dishes (10cm diameter) of A431
or A549 cells were grown to 70% confluency. A series of washes were
performed according to Sato et al, (2003), consisting of three washes
with serum-free medium (0%), 1h incubation at 371C in serum-free
medium and then two more washes with serum-free medium,and
were refreshed with 2ml of fresh serum-free medium. Ten dishes
of cells (B8.810
7cells each) were treated with 510
6 M Gefitinib,
with an equal volume of DMSO (vehicle), or were left untreated. All
dishes were then incubated at 371C. Conditioned media were
collected after 72h, pipetted into 1.5ml Eppendorfs and centrifuged
for 10min at 16000g to remove cell debris. Samples were then
concentrated using Vivascience concentrators with polyethersulfone
(PES) membranes and a filter cutoff point of 10000 MW using a
Sanyo centrifuge for 40min at the speed recommended for the
concentrator, then the concentrators were reverse -centrifuged into
the concentrate recovery cap for 4min to collect the sample. Protein
concentrations were determined by assaying samples using the
standard Bradford assay (Bradford, 1976). The samples were then
diluted with an isoelectric focusing buffer (ultra pure urea, 9.5 M in
ddH2O (Milli-Q water), 2% wv
1 of CHAPS, 1% wv
1 of DTT and
0.8% of pharmalytes (pH 3–10), 1% vv
1 phosphatase inhibitor
cocktail 2 and 4.9mgml
1 of protease inhibitor cocktail).
Running the first dimension – isoelectric focusing
The first dimension was run using an IPGphor from Amersham
Biosciences (Little Chalfont, UK) using 18cm pH 3–10 (NL)
immobilised pH gradient (IPG) strips. A 1mg volume of protein in
350ml of isoelectric focusing buffer was run under the following
conditions: instrument temperature 201C; maximum 50mAstrip;
rehydration, step 1, 30V for 12h; step 2, step-n-hold at 200V for
1h; step 3, step-n-hold at 500V for 1h; step 4, gradient at 8000V
for 1h; step 5, step-n-hold at 8000V for 4h; step 6, step-n-hold
8000V until the total volt hours reached 32000. After the run was
completed, the strips were washed in ddH2O (Milli-Q water) and
stored in 10cm tissue culture pipettes at 701C until the second
dimension was run.
Second Dimension – SDS–PAGE
SDS–PAGE gels (12%) were utilised for the second dimension.
Strips were equilibrated and then placed on the second dimension
gel and run using the following settings: a constant voltage of 250V
and settings of 300W and 50mA, until just before the dye front
reached the bottom of the gel. After completion of the run, the
gels were stained with Coomassie
s Blue G250 stain from Bio-Rad
(Hemel Hempstead, UK). Gels were then destained with ddH2O
for 2h. A digital image of gels was captured using a calibrated
scanner, ImageScannert, a flatbed optical scanner from Amer-
sham Biosciences using LabScan software from Amersham
Biosciences at 600dpi and 256 greyscales, and true colour in
transmissive mode. The scanner was calibrated using a Calibration
OD step tablet from Genomic solutions Ltd. (Huntingdon, UK).
Image analysis
The twelve 2D gels of A431 and the 12 gels of the A549 concentrated
conditioned media were analysed using Phoretixt 2D software
version 2003.02, Non-Linear Dynamics (Newcastle upon Tyne, UK)
(Mahon and Dupree, 2001). Average gels were created from the four
gels for each type of treatment: ‘Not treated’, ‘DMSO (drug vehicle)
treated’ and ‘Gefitinib’ treated, and the maximum number of gels
where the spots may be absent were one in four. Normalisation was
then undertaken and then statistical analysis of the results was
performed to display the standard deviation of the normalised spot
volumes, and a Student’s t-test was undertaken to compare
Gefitinib-treated and the DMSO control spots.
Matrix-assisted laser desorption/ionization-time of
flight(MALDI-TOF) mass spectometry
Preparation of protein spots from 2D gels for MALDI-TOF
analysis This method was an adaptation of the original
Shevchenko method (Shevchenko et al, 1996). Briefly, a 1ml
pipette tip trimmed to the size of the spot was used to cut out
colloidial Coomassie-stained spots from 2D SDS–PAGE gels. Spots
were placed in 0.5ml Eppendorf tubes prewashed with methanol
and destained using 100mM ammonium bicarbonate in 50%
acetonitrile. Samples were then washed three times in 50%
acetonitrile in ddH2O (Milli-Q water) and dried in a speed vac
from ThermoSavant (Holbrook, USA). The reduction of disulphide
bonds was performed by adding 10mM DTT (in 5mM ammonium
bicarbonate, pH 8.0) and then incubating the samples for 45min
at 501C in a heat block. Alkylation of cysteines (Herbert et al,
2001) was performed by adding 50mM Iodoacetamide (in 5mM
ammonium bicarbonate, pH 8.0) and then incubating the samples
for 1h at room temperature in the dark. The gel pieces were
washed twice in 50% acetonitrile and then dried. To perform the
in-gel digestion, B7ml of sequencing grade-modified porcine
trypsin was added to each gel piece at RT at a concentration of
20mgml
1 in 5mM ammonium bicarbonate (pH 8.0). After 5min
gel pieces were overlaid with 5mlo f5m M ammonium bicarbonate
(pH 8.0) and incubated overnight at 371C. The peptides were
extracted by centrifuging the tubes to spin liquid down from the
lid. In total,10ml 50% acetonitrile/5% trifluoroacetic acid (TFA) in
ddH2O (Milli-Q water) was added to the supernatant and it was
then transferred to fresh Eppendorf tubes. This extraction was
repeated twice and after each extraction, the supernatant was
added to the new Eppendorf tubes. The samples were then
concentrated by drying in a speed vac. The samples were stored at
201C until mass spectrometry was performed.
Analysis of peptides using MALDI-TOF mass spectrometry Pep-
tides were resuspended in 5ml of 0.1% formic acid in ddH2O
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s(Milli-Q water). The matrix used was saturated using 2,5-
dihydroxybenzoic acid (DHB) solution in 0.5ml in ddH2O (Milli-
Q water). Onto the MALDI target 0.75ml portion of the matrix was
spotted, and 0.75ml of sample was spotted on top, before the
matrix dried. MALDI-TOF mass spectra were obtained using an
Ultraflex MALDI-TOF MS from Brucker Daltonik (Bremen,
Germany) in reflectron mode with external calibration using
peptide mix standards from Brucker Daltonik (Bremen, Germany).
Peptide masses were submitted to an analysis programme, Flex
analysis from Brucker Daltonik (Bremen, Germany). Peptide
masses from the trypsin digestion were entered into the Mascot
search engine (Perkins et al, 1999) to identify proteins. Within
Mascot, four different databases were available to search from,
NCBInr, MSDB, SwissProt and OWL. Proteins were first analysed
at 50p.p.m. and then at lower sensitivities if an identification was
not made. Proteins that did not obtain significant protein
identification were not analysed further.
Confirmation of protein disulphide isomerase (PDI) upregulation
in conditioned medium of A431 cells in response to Gefitinib using
Western blotting Five 10-cm diameter plates of A431 cells were
grown to 70% confluency. Serum-free media washes were carried
out as before. Cells were then treated with Gefitinib at 510
6 M,
110
5 M, a DMSO only control, for each concentration of
Gefitinib or cells were not treated. Conditioned medium was
collected and concentrated as above. The standard Bradford assay
was performed to determine the total protein concentration,
2sample buffer was added to the samples to obtain an equal
protein load on 9% SDS–PAGE gels. Proteins were transferred
onto PVDF membranes overnight. Blots were shaken in blocking
buffer consisting of 5% wv
1 Marvel (nonfat milk powder) from
Premier Brands (Spalding, UK) in PBS/0.1% vv
1 polyoxyethylene-
sorbitan monolaurate (Tween 20) for 1h and washed in PBS/0.1%
Tween 20 (55min washes). Blots were then probed for
PDI using a rabbit anti-PDI polyclonal antibody SPA-890 from
Stressgen (Victoria, Canada) diluted to 1:1000 of the original stock
in PBS/0.1% Tween 20 for 1.5–2h. Blots were then washed in PBS/
0.1% Tween 20 (55min washes), probed with the secondary
antibody, which was a swine anti-rabbit antibody conjugated to
horse radish peroxidase (HRP) from DAKO (Cambridgeshire, UK)
at a final concentration of 1.3mgml
1 made up in PBS/0.1% Tween
20. After 1h, five final washes were undertaken in PBS/0.1% Tween
20 (55min washes), and the signal was developed using
enhanced chemiluminescent (ECL) plus from Amersham Bios-
ciences (Little Chalfont, UK) using a compact x4 hyperprocessor
from Xograph imaging systems (Tetbury, UK). The experiment
was repeated to show that the results were reproducible.
RESULTS
Two cell lines were chosen for this work, A431 cells derived from
a vulval squamous cell cancer and A549 cells from an adeno-
carcinoma of the lung. These were selected as they are known to
express high levels of the EGFR (A431 210
6 and A549 510
5
respectively) and to be dependant on activity of the EGFR for
sustained growth. Moreover, A431 cells are a well established
model in EGFR research, and the A549 cells are from a common
cancer type in which the effects of Gefitinib have been evaluated
in clinical trials. We first tested their sensitivity to Gefitinib by
treating A431 cells with EGF in the absence or the presence of
increasing drug concentrations. Gefitinib is rather insoluble in
water, so this was dissolved in DMSO and, thus, a vehicle-only
control was included in all subsequent experiments. There was, as
predicted, a progressive inhibition of receptor phosphorylation
on tyrosine with increasing drug dose as previously reported.
Substantial inhibition was seen at 510
6 M Gefitinib, which was
therefore used in subsequent experiments.
Cells were grown and treated with DMSO alone, Gefitinib was
dissolved in DMSO or was untreated for 72h and serum-free
conditioned medium containing secreted proteins was prepared
for 2D gel separation, as described in the Materials and Methods
section. Isoelectric focusing was undertaken using 18cm immo-
bilised nonlinear pH 3–10 gradient strips, and the second
dimension separation was performed using 12% denaturing SDS
gels. In each case, four replicate gels were run for each condition.
The separated proteins were detected using colloidal coomassie
blue G250 staining, and digital images of the gels were acquired.
Figure 1A and B show gels of proteins secreted from the A431 and
A549 lines. Reference gels were created for each condition, and the
Phoretix software was used to detect spots which were upregulated
or downregulated significantly between cells treated with vehicle
only or the drug in DMSO, and these were divided into those
whose expression varied up to 1–2-fold and those which changed
two-fold or more. The proteins selected using the Phoretix
software were analysed further using the Student’s t-test, and the
protein spots shown to display significant changes using both
types of analysis were prepared for mass spectrometry (Figure 1C
and D). From the Student’s t-test analysis, six protein spots were
identified from conditioned medium from A431 cells with a
significant change in expression of more than two fold, four
were upregulated and two were downregulated. Twelve spots which
varied by 1–2-fold, were detected eight were reduced and four
increased. Seven protein spots from conditioned medium from
A549 cells were altered more than two-fold (three upregulated and
four downregulated) and ten spots changed 1–2-fold (six
upregulated and four downregulated).
We next sought to identify each of the proteins which were
changed in expression significantly according to the Student’s
t-test. Individual protein spots were excised from the gels and
subject to tryptic digestion and MALDI-TOF mass spectrometric
analysis. Mascot software was employed to identify proteins from a
comparison of their mass fingerprints with up to four databases as
described in the Materials and Methods section and those with a
significant score are listed (Figure 1C and D and Supplementary
Tables 1 and 2).
One protein from A431 cells gave a particularly large increase
in expression levels. This was identified by MALDI-TOF mass
spectrometry (at a significant score) as protein disulphide
isomerase. In order to provide independent validation of the
original experiments, we treated new cultures of cells and again
collected conditioned medium using the two drug concentrations,
510
6 M and 110
5 M. Samples of untreated, vehicle–only-
treated and drug in DMSO-treated cell conditioned medium, were
analysed using Western blotting, and an antibody specific for
human PDI was utilised to detect the expression of this protein in
the mixture. Protein disulphide isomerase was upregulated as seen
in the 2D gels, and this was proportional to the concentration of
the drug. Scanning the autoradiograph to estimate the effects on
expression levels showed an approximately six-fold induction of
expression at the highest level of drug added (Figure 2).
DISCUSSION
In this work using a model system, we have shown that it is possible
to detect reproducible changes in expression levels of a range of
proteins secreted from cancer cells. Two processes of statistical
validation of the identification of individual proteins were applied.
First, the change in level of expression of equivalent spots had to
reach significance using the standard deviation of the normalised
spot volumes and also a Student’s t-test comparing Gefitinib-
treated and DMSO-treated gels. Second, the identification of the
proteins from this set of spots as known proteins using MALDI-
TOF mass spectrometry and the Mascot search engine had to be
significant at 50p.p.m. (the detailed data are presented in
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Figure 1 Results of image analysis undertaken of an average (A) A431 and (B) A549 Colloidal Coomassie Blue-stained 2D gel of concentrated
conditioned medium displaying all the protein spots which are upregulated 2-fold (pink), upregulated 1-2-fold (blue), downregulated two-fold (green) or
downregulated between 1- and 2-fold (red) in response to Gefitinib. Spots missing from Gefitinib-treated gels are marked in yellow and spots missing from
not-treated gels and DMSO-treated gels (purple). A few example spots which do not change in response to Gefitinib are also marked using black circles.
Protein spots from (C) A431 and (D) A549 cells which display significant changes in protein expression in response to Gefitinib compared with the DMSO
vehicle control using the Student’s t-test at the ***Po0.01, **Po0.05 or *Po0.1 level and which have been analysed using MALDI-TOF mass
spectrometry.
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sSupplementary Tables 1 and 2). After this rigorous selection
process, six of the 12 proteins upregulated by Gefitinib in A431 cells
were identified. Three spots were identified as members of the heat-
shock family HSP70 protein family. Spots 2 and 4 were both heat
shock protein 70 protein 8 isoform 1, and the other, spot 3, was
chain A of heat shock 70. Heat-shock proteins (HSP) are comprised
of four major families, the small HSP (sHSP) family, the HSP60
family, the HSP70 family and the HSP90 family, and these families
are classified according to the molecular weight of the protein.
Therefore, heat shock 70-kDa protein 8 isoform 1 belongs to the
HSP70 family. The HSP70 family is induced by stress, for example,
caused by the effect of a drug or disease, and HSP70 is upregulated
in many cancers (Lichtenfels et al, 2002) including breast, gastric,
prostate and colorectal cancer. Heat-shock protein 70 is also
involved in correct protein folding, assembly of newly synthesised
proteins and the disassembly of protein aggregates. Heat-shock
proteins are also regulators of apoptosis which could be occurring
in response to Gefitinib. Heat-shock proteins were originally
reported to be located in the cytoplasm or ER of the cell, but
HSP70 is found on the cell surface (Shin et al, 2003) and in normal
peripheral blood (Wehner et al, 2003). The heat-shock 70-kDa
protein 1 (HSP70.1) is also a member of the HSP70 family and has a
number of roles in the cell including, chaperon function, stabilising
proteins against aggregation and facilitating protein folding in the
cytosol and in organelles (Milner and Campbell, 1990). Heat-shock
70-kDa protein 1 (HSP70.1) and three other members of the HSP70
family (GRP78, HSC70 and GRP75) are upregulated in cancerous
tissue (Takashima et al, 2003). Consistent with our data Shin et al,
(2003) have studied the global cell surface proteome of a number of
cancer cells (including the A549 cell line) and found a surprising
abundance of chaperones including GRP78, GRP75 and notably
HSP70, HSP60, HSP54 and HSP27.
Two further proteins upregulated in A431 conditioned medium
are PDI and its precursor PDI ER60. Protein disulphide isomerase
is involved within the ER in folding proteins which contain
disulphide bonds (Freedman et al, 1994; Jiang et al, 1999; Herbert
et al, 2001). In addition, it has been shown that PDI can protect
neurons and endothelial cells from hypoxic cell death (Sullivan
et al, 2003). It is also located in other organelles and is also
secreted from the cell (Yoshimori et al, 1990). ER60 (Erp60), also
called Erp57, is a protein disulphide isomerase precursor, a human
glucose-regulated protein and the closest-known homologue of
PDI (Frickel et al, 2004) sharing 33% of the same amino acids as
PDI. ER60 is expressed in response to conditions of stress (Ferrari
and Soling, 1999). ER60 was found to show a two-fold upregulation
in response to Gefitinib compared with untreated and DMSO-
treated A431 cells conditioned medium.
Finally, in conditioned medium from A431 cells, the protein
alpha enolase was found to be induced 1–2-fold. Alpha enolase is
a cytoplasmic glycolytic enzyme (Chang et al, 2003) and is
downregulated in non-small-cell lung carcinoma, and so the
upregulation of this protein with Gefitinib could play a part in the
reversal of tumorigenesis. Alpha enolase belongs to a group of cell-
surface proteins (Pancholi, 2001) and has been proposed as a
biochemical marker in myocardial damage detection (Mair, 1997)
and a neuron-specific form of the protein has been proposed as a
tumour marker in oncology (Jacobs and Haskell, 1991).
Two proteins were identified in the secretome of A549 cells,
the A chain of triosephosphate isomerase (TIM) (downregulated
42-fold) and the S100C calcium-binding protein A1 (upregulated
1–2-fold). The upregulation of S100C in response to Gefitinib was
confirmed by Western blotting (data not shown). Triosephosphate
isomerase (TIM) is an enzyme which catalyses the interconversion
between D-glyceraldehyde-3-phosphatate and dihydroxyacetone
phosphate. An autoantibody to TIM is found in the serum of
patients with osteoarthritis (Xiang et al, 2004) and in patients with
neuropsychiatric lupus (Watanabe et al, 2004). Triosephosphate
isomerase was also found to be significantly overexpressed in lung
adenocarcinoma consistent with its detection in the conditioned
medium of the A549 cell line (Chen et al, 2002). S100C is a
calcium-binding protein involved in cell cycle progression and
differentiation, which is localised in the cytoplasm and nucleus of
many cell types. This protein has been shown to be downregulated
in a range of malignant tissues, compared to normal tissues
including the bronchus, mammary duct, renal tube, prostate,
uterus and testis. therefore, this protein could be a candidate for a
new tumour marker (Kondo et al, 2002). S100C secretion is
upregulated in response to Gefitinib and, therefore, Gefitinib could
be, in part, reversing the malignant phenotype.
Collectively, the proteins identified here are involved in the cells
response to stress. Although Gefitinib was designed to target
specifically the EGFR, it is now clear that it can bind to and inhibit
with differing affinities, at least 27 kinases (Brehmer et al, 2005).
It is likely that when other SMTKIs are examined in more detail
they will also have a range of ‘on-target’ and ‘off-target’ effects. It
will be interesting to see, however, if the responses to them share
similarities such as inducing the expression of stress response
proteins. If so, these might be useful markers for drug activity
since ultimately the desired effect is death of the cancer cells.
In summary, the work presented here demonstrates that it is
possible to detect proteins whose secretion into the medium is
altered by treatment with an inhibitor of the EGF receptor. In one
case, this appeared to be concentration dependent. Clearly in order
to be of practical use, such markers should be secreted by particular
cancer types. It may then be possible to develop this approach to
make sensitive assays which could be tested on serum obtained from
animals bearing xenografted human tumours and in, in the future,
patient’s serum as a surrogate assay for drug activity.
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